ISTH Academy

Create Account Sign In
Maximum: 2 CME cr.
0 new discussion posts (84 published)
Sign in to view your progression
Program Overview Progr...
Learning Objectives Learn...
Target Audience Targe...
Credit Designation Credi...
Disclosure/Disclaimer Discl...

Activity Title

Cancer-Associated Thrombosis Course


Prevention and treatment of  cancer-associated thrombosis

Accreditation Type

AMA PRA Category 1 Credit(s)

Release Date

December 11, 2020

Expiration Date

December 11, 2021

Estimated Time to Complete Activity

120 minutes


Statement of Need:

Cancer-associated thrombosis (CAT) is a major cause of mortality in cancer patients. Although potentially fatal, CAT is both preventable and treatable if caught in time. This course is designed to provide health care professionals caring for patients with CAT an overview on prevention and management methods using evidence-based guidelines.


Marc Carrier, MD, MSc, FRCPC

Associate Professor of Medicine

Senior Scientist, Clinical Epidemiology Program

The Ottawa Hospital Research Institute

Ottawa, Canada


Alok A. Khorana, MD

Professor of Medicine

Cleveland Clinic Lerner College of Medicine

Case Western Reserve University

Cleveland, OH


Simon Noble, MD

Marie Curie Professor of Supportive and Palliative Medicine

Division of Population Medicine

Cardiff University

Cardiff, Wales


Tzu-Fei Wang, MD

Associate Professor of Medicine

The Ohio State University

Columbus, OH


CME credit for this activity expired on December 11, 2021.  If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or

Educational Activity Learning Objectives:

Upon completion of this course, the participants should be able to:

Module 1: Primary Thromboprophylaxis in Ambulatory Patients with Cancer

  • Identify ambulant cancer patients risk for VTE
  • Identify patients who may benefit from primary prevention
  • Discuss type, dose and duration of anticoagulation for primary prevention of cancer-associated VTE

Module 2: Treatment of Cancer-Associated Thrombosis

  • Describe the epidemiology and clinical relevance of venous thromboembolic (VTE) complications in cancer patients
  • Identify treatments for the acute and long-term treatment of cancer-associated thrombosis (CAT)
  • Strategize how to use DOACs for the management of cancer-associated thrombosis and the clinical characteristics to consider in tailoring anticoagulation management for the treatment of CAT

Target Audience:

This cancer-associated thrombosis (CAT) course is intended for general hematologists, physicians, and other health care professionals who care for patients with cancer around the world.

CME Credit for this activity expired on December 11, 2021  

Accredited Provider  

Jointly provided by The France Foundation and The International Society on Thrombosis and Haemostasis.

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and The International Society on Thrombosis and Haemostasis. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation


The France Foundation designates this internet live course for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support Acknowledgement

This activity was previously supported by an educational grant from Bayer (2019-2020).

This activity is currently supported by The International Society on Thrombosis and Haemostasis.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and The International Society on Thrombosis and Haemostasis (ISTH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.


Activity Staff Disclosures:

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at The International Society on Thrombosis and Haemostasis who control content have no relevant financial relationships to disclose.


Faculty Disclosures:

The following faculty report that they have relevant financial relationships to disclose:

  • Dr. Marc Carrier has consulted (non-CE) for Bristol Myers Squibb, Sanofi, Servier, and Leo Pharma. He has served as contract researcher for Bristol Myers Squibb, Pfizer, and Leo Pharma.
  • Dr. Alok A. Khorana has consulted (non-CE) for Janssen, Bayer, Bristol Myers Squibb, Pfizer, Sanofi, Halozyme, Parexel, and SeaGen.

The faculty listed below report that they have no relevant financial relationships to disclose:

  • Dr. Simon Noble
  • Dr. Tzu-Fei Wang

Disclosure of Unlabeled Use

TFF and ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.


The France Foundation and The International Society on Thrombosis and Haemostasis present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The International Society on Thrombosis and Haemostasis, and the former commercial supporter assume no liability for the information herein.

Copyright Information

Copyright © 2020 by The International Society on Thrombosis and Haemostasis. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

•             The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

•             Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

Privacy Policy

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at

Module1 : Primary Thromboprophylaxis in Ambulatory Patients with Cancer
Module 2: Treatment of Cancer-Associated Thrombosis
Post-Test, Evaluation & Certificate

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies